Journal
COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 187, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.colsurfb.2019.110747
Keywords
Lycium barbarum; Lipid; Nanoparticle; Oral administration; Ulcerative colitis; Treatment
Funding
- National Natural Science Foundation of China [81571807]
- Fundamental Research Funds for the Central Universities [XDJK2019TY002]
- Venture & Innovation Support Program for Chongqing Overseas Returnees [cx2018029]
- Chinese Scholarship Council
Ask authors/readers for more resources
Edible plant-derived nanoparticles (NPs) have attracted increasing attention in the treatment of ulcerative colitis (UC). Lycium barbarum (LB), a popular functional fruit, possesses various biological functions. Here, fat-soluble contents were extracted from LB and further processed into LB lipid-derived NPs (LBLNs). The resultant NPs had an average hydrodynamic diameter around 189.2 nm, narrow size distribution (polydispersity index=0.2), and negative surface charge (-34.9 mV). Moreover, they could be efficiently taken up by UC therapy-related target cells (macrophages), and over 69.0 % of macrophages internalized LBLNs after 4 h co-incubation. We further found from the in vitro results that LBLNs had strong capacities to inhibit the secretion of the main pro-inflammatory cytokines (TNF-alpha and IL-12) and up-regulate the expression of the typical anti-inflammatory factor (IL-10). Finally, mice experiments confirmed that LBLNs after oral administration could specifically accumulate into inflamed colon tissues, and further attenuate UC-relevant symptoms (e.g., bodyweight loss, colon shortening, increase of spleen weight, and histopathological appearance, as well as ulceration). Collectively, this study demonstrates the excellent therapeutic outcomes of LBLNs against UC and provides a promising edible nanotherapeutic for UC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available